How can my 29-year-old sister manage her NMOSD?

Question

Hello doctor,

My 29-year-old sister was diagnosed with neuromyelitis optica spectrum disorder 18 months ago and has been struggling terribly with frequent relapses. She has had three severe, devastating attacks, two causing significant vision loss and one spinal attack, leaving persistent leg weakness and difficulty walking. High-dose steroids during relapses help somewhat but cause terrible weight gain, severe mood swings, and insomnia lasting weeks after treatment.

The neurologist started Rituximab infusions for prevention, but she is still having breakthrough attacks, and we are extremely worried about accumulating permanent disability. Vision loss in her right eye has not recovered at all, and she is absolutely terrified about losing sight in her left eye completely. Walking is increasingly difficult due to spasticity and numbness, and she needs a cane for stability most days now.

She had to leave her job because the unpredictability of attacks makes maintaining a consistent work schedule impossible. The emotional toll is devastating; she goes from completely normal functioning to severely disabled within days during acute relapses.

Are there newer, more effective preventive treatments or more aggressive immunosuppressive therapies that might actually stop these attacks? Each relapse seems to leave her with more permanent neurological damage and disability.

Please advise.

Thank you.

Answer 1

Hello,

Welcome to icliniq.com.

I am truly sorry your sister is going through this. Neuromyelitis optica spectrum disorder (NMOSD) can indeed be very aggressive and emotionally draining for both the patient and the family. Let me explain her situation clearly and what modern options exist.

NMOSD is caused by the immune system attacking a specific protein (often aquaporin-4) on nerve cells in the optic nerves and spinal cord. Each relapse can cause permanent injury, so preventing future attacks is the most critical goal. Rituximab (a B-cell–depleting antibody) has been standard for years, but some patients still experience relapses even with proper dosing.

Sometimes relapses occur if the B-cells repopulate too early, meaning the next Rituximab infusion might be needed sooner or at a higher dose. Blood CD19 (cluster of differentiation 19)/CD20 counts help guide timing. Ensuring no missed doses and screening for infections or overlapping autoimmune issues is also important.

Several modern targeted treatments have shown excellent results in preventing relapses:

Eculizumab (Soliris): Blocks the complement system that damages nerve cells; extremely effective but requires infection prevention (especially meningococcal vaccination).
Inebilizumab (Uplizna): Similar to Rituximab, targets B cells more broadly and lasts longer between doses.
Satralizumab (Enspryng): Blocks interleukin-6 (IL-6) pathway; available as an injection and has a good safety profile. These are approved in many countries for aquaporin-4 antibody–positive NMOSD and have significantly reduced relapse rates compared to traditional immunosuppressants.

Spasticity and stiffness can improve with Baclofen, Tizanidine, or physiotherapy. Vision rehabilitation and low-vision aids can also help her adapt. It is natural for her to feel anxious and hopeless after repeated attacks. Counseling or joining an NMOSD support group often helps patients regain confidence and emotional strength.

She should have her case reviewed by a neurologist specializing in neuroimmunology or NMOSD to confirm antibody status, evaluate whether Rituximab levels are adequate, and discuss switching to one of the newer biologic treatments.

In short, there are newer, stronger options like Eculizumab, Inebilizumab, and Satralizumab that can drastically reduce relapses and protect her remaining vision. With the right plan, her risk of further severe attacks can be much lower, and her quality of life can improve.

I hope my explanation has been clear and sufficient for you, and I am always available if you have any questions.

Thank you.